In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

(UroToday.com) The 2024 IBCN annual meeting included a session on molecular subtyping in the 2024, featuring a presentation by Dr. Saum Ghodoussipour discussing the LUMBER-NAC trial in progress. A ...

IBCN annual meeting included a session on novel therapies and outcome measures in clinical trials, featuring a presentation by Dr. Gautier Marcq discussing the benefit of whole-pelvis radiation for ...

IBCN annual meeting included a keynote lecture by Dr. Niko Beerenwinkel discussing inferring tumor evolution from single-cell data. Although the majority of work has been done in other cancers (ie.

IBCN annual meeting included a bladder cancer session, featuring a presentation by Dr. Amanda Myers discussing the ...

Undetectable pre-cystectomy ctDNA predicts better pathological outcomes post-radical cystectomy Patients with undetectable pre-cystectomy status demonstrated recurrence-free survival, regardless of ...

There were 137 patients included in this study with a median age of 71.8 years (range 50.1-92.8). There were 77.4% of patients that presented de novo stage IV, 16.1% with visceral metastasis, and 53.3 ...

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Praful Ravi discussing the determination of tumor PSMA expression in prostate cancer ...

ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo ...

CYCLONE 2: A Phase 3 Study of Abemaciclib with Abiraterone in Patients with mCRPC Matthew Smith, MD, Ph.D. Matthew Smith presented results from the CYCLONE 2 trial, which evaluated abemaciclib plus ...

Topography and Lateralization of Nodal Metastases in Muscle-Invasive Bladder Cancer Using Super-Extended Pelvic Lymph Node Dissection with the Sentinel Lymph Node Technique. September 19, 2024 ...